Trans-Pacific Partnership Agreement Hits Turbulence Over Pharma IP Provisions
This article was originally published in PharmAsia News
The nine countries negotiating the free trade agreement disagree on text for the intellectual property chapter; pharma continues to push for 12 years of biologics data exclusivity while generic associations oppose that and other IP proposals.
You may also be interested in...
At a House hearing PhRMA representative cites the need for 12 years test data exclusivity for biologics in the Trans-Pacific Partnership Agreement. Separately, USTR issues its 2012 Special 301 Report.
As the U.S. enters the eighth round of negotiations over the Trans-Pacific Partnership Agreement, non-government organizations and the generic drug industry are speaking out against intellectual property proposals backed by brand-name pharma.
Teva and US FDA disagree over whether Copaxone is a protein. While generics are already on the market, Teva wants to assert process patents against future would-be competitors, which the firm cannot do through the ANDA pathway.